BioMark Diagnostics, Inc. (OTCQB: BMKDF) is an oncology-focused company on a mission to develop and market cutting-edge technologies to increase prediction and accuracy in the diagnosis of cancers. The company develops metabolomics-based diagnostic assays for the ultra-early detection of cancer before tumors become metastatic and symptomatic. BioMark presently has a promising anti-body based cancer treatment and advanced stage diagnostic technologies (originally licensed from the University of Manitoba, Canada) in the pipeline. For more information, visit the company’s website at www.biomarkdiagnostics.com